Apr 12, 2019 8:00 am EDT CymaBay Therapeutics Presents Positive Phase 2 Data for Seladelpar in Patients with Primary Biliary Cholangitis at the International Liver Congress™ 2019
Mar 27, 2019 8:00 am EDT CymaBay Therapeutics Announces Multiple Presentations During The International Liver Conference™ 2019
Mar 11, 2019 12:05 pm EDT CymaBay Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Feb 28, 2019 4:05 pm EST CymaBay Reports Fourth Quarter and Fiscal Year End 2018 Financial Results and Provides Corporate Update
Feb 21, 2019 8:00 am EST CymaBay Therapeutics to Report Fourth Quarter and Fiscal 2018 Financial Results on Thursday, February 28
Feb 20, 2019 8:00 am EST CymaBay Therapeutics to Present at the 8th Annual SVB Leerink Global Healthcare Conference
Feb 19, 2019 8:00 am EST CymaBay Therapeutics Announces Early Enrollment of a Phase 2b Study of Seladelpar in Patients with Nonalcoholic Steatohepatitis